On this episode of Stock Movers:
- Sanofi’s experimental drug for the skin condition atopic dermatitis disappointed investors in a late stage trial, after the benefit of the drug was less than expected. 
- Jet2 fell 25%. Trading volume was six times the average for this time of day. The stock reversed the previous session's gain.
- A year after losing its spot in Britain’s blue-chip benchmark, Burberry is returning to the UK’s stock-market elite. The luxury-goods maker, best known for its tartan-plaid trench coats, will rejoin the FTSE 100 Index later this month, index compiler FTSE Russell said Wednesday.

On this episode of Stock Movers: - Sanofi&rsquo;s experimental drug for the skin condition atopic dermatitis disappointed investors in a late stage trial, after the benefit of the drug was less than expected. - Jet2 fell 25%. Trading volume was six times the average for this time of day. The stock reversed the previous session's gain. - A year after losing its spot in Britain&rsquo;s blue-chip benchmark, Burberry is returning to the UK&rsquo;s stock-market elite. The luxury-goods maker, best known for its tartan-plaid trench coats, will rejoin the FTSE 100 Index later this month, index compiler FTSE Russell said Wednesday.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Sanofi Drops, Jet2 Warning, Burberry Rise

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/c4c086b6-4e6b-42bc-ad21-b34e0085a4df/transcript

Advertisement